Product Detail


Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

CAS No. 571189-49-6, 5-(4-methylpiperazin-1-yl)pyridin-2-amine

  • 571189-49-6

  • C10H16N4

  • 192.26

  • 1.142±0.06

  • 98.0%

  • 148

  • Light yellow to Brown


  • Trilaciclib

  • 7/23/2039 (Trilaciclib)

  • CDK4/6

  • N

  • 2020

  • ISO 9001;ISO 14001;ISO 45001; GMP


Product Description

Trilaciclib revolutionizes the landscape of oncology therapeutics by protecting and preserving patients' bone marrow during chemotherapy. Trilaciclib's unique mechanism reduces the risk of chemotherapy-induced myelosuppression, enabling patients to undergo more effective and intensive treatment regimens. By ensuring a safer and more productive treatment journey, Trilaciclib optimizes patient outcomes and strengthens your company's commitment to advancing cancer care. Embrace this game-changer and pave the way for a new era in cancer therapeutics.